MedTrace Logo

Clinical Research of 18F-Alfatide Ⅱ PET/CT in Breast Cancer

NCT02582801 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2019-09-27

No results posted yet for this study

Summary

18F-Alfatide Ⅱ PET/CT in breast cancer patients

Conditions

Interventions

DRUG

18F-Alfatide Ⅱ PET/CT

Inject 18F-Alfatide Ⅱ by vein and then perform PET/CT scan after 60 min

Sponsors & Collaborators

  • Jiang Wu

    lead OTHER

Principal Investigators

  • Guangming Lu, Professor · Jinling Hospital, China

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-31
Primary Completion
2018-10-31
Completion
2019-09-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02582801 on ClinicalTrials.gov